Testing SMA patient DNA with advanced methods like HapSMA can reveal genetic changes that affect how severe the disease is, ...

Those with spinal muscular atrophy can get emotional support by building an SMA support system that includes SMA communities ...

Evidence suggests inbreeding heightens the risk of birth defects and developmental delays, such as learning and speech ...

Purpose: X-linked infantile spinal-muscular atrophy (XL-SMA) is a rare disorder, which presents with the clinical characteristics of hypotonia, areflexia, and multiple congenital contractures ...

Spinal muscular atrophy (SMA) is a disorder affecting the motor neurons—nerve cells that control voluntary muscle movement. These cells are located in the spinal cord. Because the muscles cannot ...

A rare genetic condition, Spinal Muscular Atrophy (SMA) affects one in 7,000 people in India. It mostly affects children and often leads to infant mortality In a breakthrough for Spinal Muscular ...

In what could be promising news for patients battling spinal muscular atrophy (SMA), the Delhi High Court has refused to allow a suit by Swiss pharma giant Roche seeking to restrain Indian drugmaker ...

an oral medicine for Spinal Muscular Atrophy (SMA). Loading content, please wait ...

22. Apitegromab is an investigational treatment aimed at improving motor function for people living with spinal muscular atrophy. Scholar Rock said it has also submitted and received validation ...

for apitegromab for the improvement of motor function in patients with spinal muscular atrophy (SMA). Apitegromab, a fully human monoclonal antibody, works by selectively binding to the pro- and ...

22, 2025. Scholar Rock announced today that the FDA granted priority review for a biologics license application (BLA) for apitegromab, a treatment for spinal muscular atrophy (SMA), according to a ...

an oral medicine for Spinal Muscular Atrophy (SMA). In what could be a significant ruling, the Court has held that the public good outweighs the profits of a company, considering that the drug is not ...